pdufa.bio

MAR002 Phase

Page updated ·next FDA decision on the calendar ·Data as of Oct 11, 2026 9:31 PM ET

MAR002 Phase is a LISATA THERAPEUTICS, INC. program in acromegaly. Its next catalyst is a Readout in Q4 2027. Every date links its source.

LSTA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: acromegaly. Sponsor: LISATA THERAPEUTICS, INC. (LSTA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027LSTA

Questions

When is MAR002 Phase's next FDA decision or readout?

The next tracked catalyst for MAR002 Phase is a Readout in Q4 2027.

What happened at MAR002 Phase's most recent FDA decision?

No FDA decision for MAR002 Phase is in our archive yet.

What is MAR002 Phase used for?

In our records MAR002 Phase is under review or in development for acromegaly.

Who makes MAR002 Phase?

LISATA THERAPEUTICS, INC. (LSTA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.